Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Gross Profit: 2016-2023

Historic Gross Profit for Seres Therapeutics (MCRB) over the last 8 years, with Dec 2023 value amounting to $126.3 million.

  • Seres Therapeutics' Gross Profit was N/A to $351,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $107,000, marking a year-over-year change of. This contributed to the annual value of $126.3 million for FY2023, which is 1672.24% up from last year.
  • Per Seres Therapeutics' latest filing, its Gross Profit stood at $126.3 million for FY2023, which was up 1,672.24% from $7.1 million recorded in FY2022.
  • In the past 5 years, Seres Therapeutics' Gross Profit ranged from a high of $144.9 million in FY2021 and a low of $7.1 million during FY2022.
  • Its 3-year average for Gross Profit is $92.8 million, with a median of $126.3 million in 2023.
  • Its Gross Profit has fluctuated over the past 5 years, first tumbled by 95.08% in 2022, then surged by 1,672.24% in 2023.
  • Yearly analysis of 5 years shows Seres Therapeutics' Gross Profit stood at $34.5 million in 2019, then fell by 3.74% to $33.2 million in 2020, then surged by 336.33% to $144.9 million in 2021, then plummeted by 95.08% to $7.1 million in 2022, then spiked by 1,672.24% to $126.3 million in 2023.